Abstract While surgery is the usual treatment for localized well-differentiated and dedifferentiated liposarcomas (WDLPS/DDLPS), the therapeutic options for patients with advanced disease are limited. The classical antimitotic treatments are most often inefficient. The establishment of genetically characterized cell lines is therefore crucial for providing in vitro models for novel targeted therapies. We have used spectral karyotyping, fluorescence in situ hybridization with whole chromosome painting and locus-specific probes, and array-comparative genomic hybridization to identify the chromosomal and molecular alterations of a novel cell line established from a recurring sclerosing WDLPS. The karyotype was hypertriploid and showed multiple structural anomalies. All cells retained the presence of a giant marker chromosome that had been previously identified in the primary cell cultures. This giant chromosome contained high-level amplification of chromosomal regions 12q13-21 and lacked the alpha-satellite centromeric sequences associated with WDLPS/DDLPS. The 12q amplicon was large, containing 370 amplified genes. The DNA copy Florence Pedeutour and Georges Maire contributed equally to the work.
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Introduction
Well-differentiated and dedifferentiated liposarcomas (WDLPS/DDLPS) are the most frequent sarcomas in adults [1] [2] [3] . Histologically, WDLPS are made up of mature adipocytes, atypical cells, and lipoblasts. They are considered as tumors of intermediate malignancy because they demonstrate a high rate of recurrence but rarely metastasize. When mature adipocytes are prominent within a WDLPS, the main differential diagnosis is deep-seated lipoma or intramuscular lipoma. In approximately 10 % of cases, a poorly differentiated component is present and the tumor is classified as DDLPS [3, 4] . Most often, the transition between welldifferentiated and non-lipogenic areas is abrupt. Difficulties for diagnosing DDLPS arise when the poorly differentiated component predominates. The distinction between DDLPS and poorly differentiated tumors can be hard in such cases.
Molecular cytogenetic analyses are valuable ancillary tools for correct recognition of WDLPS and DDLPS. Indeed, both are characterized by the presence of giant marker or ring chromosomes, containing amplification of the 12q14-15 chromosomal region [5] . The amplified 12q14-15 region consistently contains the MDM2 gene, located at 12q15, and co-amplification may involve several other genes, including HMGA2 (12q14.3), CDK4, SAS/TSPAN31 (12q14.1), YEATS4 [6] [7] [8] , CPM [9] , and FRS2 [10] (12q15).
During the last decade, genomic studies have consistently improved the characterization of WDLPS/DDLPS. However, many points still need to be clarified concerning the biology, pathogenesis, and clinical management of these tumors. First, the mechanism of generation of the large marker chromosomes containing the amplified regions remains obscure. Numerous chromosomal regions have been described to be variably co-amplified with the 12q14-15 amplicon [5, 6, 8, 9, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Moreover, the marker chromosomes present unusual centromere alterations that suggest a peculiar way of formation [15, 23] . Second, while surgery with or without radiotherapy is the usual treatment for localized WDLPS/DDLPS, the therapeutic options for patients with advanced disease are very limited. The classical antimitotic treatments such as doxorubicin or ifosfamide show low response rates [24] . Therefore, there is an urgent need for novel targeted therapies against WDLPS/DDLPS. Several strategies such as those targeting P53 or the JUN/JUNK pathways are currently studied [20, 25] . However, the lack of model systems impairs the development of new treatments. Indeed, WDLPS/DDLPS are difficult to grow in vitro. Most primary cultures do not provide enough material for extensive genomic and pharmacological studies. To our knowledge, only a few human cell lines, such as LS141, DDLS [26] , FU-DDLS-1 [27] , LS14 [28] , LPS695, LP6 [29] , GOT3 [30] , 93449, and 94778 [6, 15] , have been described as arising from WDLPS/DDLPS. We report here the molecular and cytogenetic characterization of a novel WDLPS cell line designated 95T1000.
Materials and methods

Clinical information and histological analysis
A 43-year-old man without significant medical history presented in 1990 with a swollen thigh. The tumor was located within the adductor muscles. Histologically, the surgical specimen showed two components: a sclerosing WDLPS zone without any necrotic area or mitotic activity and a cellular dedifferentiated area containing short spindle cells organized in a cartwheel pattern. Tumor cells of the dedifferentiated area presented hyperchromatic irregular nuclei, with low mitotic activity. Zones of tumor necrosis were present. Transition between WDLPS and poorly differentiated zones was abrupt. The diagnosis was sclerosing WDLPS with dedifferentiated zones of grade II malignancy. The metastatic workup, including a chest computed tomography scan, was negative. Surgery was considered as R0 [31] and adjuvant radiotherapy (50 Gy) was delivered.
A local recurrence presented in October 1995. The tumor measured 14×7.5 cm and was macroscopically well-delineated. Histologically, the tumor presented the features of a sclerosing WDLPS without any necrotic area or mitotic activity (Fig. 1a) . Preoperative radiotherapy (45 Gy) was delivered. Immunohistochemistry showed strong expression of MDM2 protein (Fig. 1b) . A second grade I sclerosing WDLPS recurrence presented in October 1997. The diagnosis of sclerosing WDLPS was established according to the World Health Organization Classification of Tumors [1, 32] .
Establishment of the cell line and molecular cytogenetic analysis
Fresh tumor material from the first recurrence in 1995 was reserved for cell culture and cytogenetic analysis following surgical excision. Tumor tissue was disaggregated and cells from short-term cultures (10 days) were used for metaphase chromosome preparations according to established procedures [33] . Meanwhile, tumor cells were maintained in culture in RPMI 1640 medium (Gibco BRL, Life Technologies, Grand Island, NY, USA) supplemented with 10 % fetal calf serum (Gibco). Karyotype analyses of the 95T1000 cells were performed at passages 4, 10, 12, 31, 34, 54, 59, 60, 61, 69, and 80 (P80). Metaphase cells were analyzed by reverse banding using heat and Giemsa (RHG).
Spectral karyotyping (SKY) was performed on metaphases from P80 according to the manufacturer's instructions (Applied Spectral Imaging, Carlsbad, CA, USA) and as previously published [34, 35] . Fluorescence in situ hybridization (FISH) analyses were performed on metaphase and interphase cells. The FISH probes used for our study are listed in Table 1 [6] .
Array-comparative genomic hybridization analyses DNA was extracted using Qiagen Blood and Tissue DNeasy Kit (Doncaster, Victoria, Australia) following the manufacturer's instructions. Array-comparative genomic hybridization (aCGH) analysis was performed on 95T1000 and normal female reference DNA (Promega, Madison, WI, USA) using Affymetrix 250K NspI SNP microarrays (nominal average resolution, 1-5 kb), according to manufacturer's instructions (Affimetrix, Santa Clara, CA, USA). Copy number analysis of the 250K Nsp data was initially processed using Affymetrix Genotyping Console (GTC3.0.1) and subsequently analyzed using the Partek suite of software (St. Louis, MO, USA) as previously described [36] . Copy number information was derived after normalizing to the control reference DNA, and chromosome gains and losses were expressed as estimated relative copy number (ECN). The Partek segmentation algorithm used a minimum of one feature per region, a P value threshold of <0.00001, a signal-to-noise ratio of 0.3, and an expected range of 0.3 (Table S1 ).
Real-time quantitative RT-PCR
Real-time quantitative RT-PCR (qRT-PCR) was used to determine the expression levels of GLI1, DDIT3, CDK4, TSPAN31, MDM2, YEATS4, WIF1, HMGA2, CDKN2A (p16INK4a and p14ARF), CCND1, and RB1. Total RNA was extracted from the 95T1000 cells (P57) and from short-term cultures of normal adipose tissue using Trizol TM (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. The RNA samples were treated with DNA-free™ (Applied Biosystems, Foster City, CA). The quality of RNA was evaluated using the 2100 BioAnalyser and RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA). One microgram of total RNA was reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Each quantitative PCR (Q-PCR) experiment was performed twice using either fluorescein amidite dye for MDM2, CDK4, DDIT3, YEATS4, HMGA2 (exons 1-2), HMGA2 (exons 3-4), HMGA2 (exons 4-5), TSPAN31, GLI1, WIF1, p14ARF, CCND1, RB1, or SYBRGreen dye for p16INK4a according to the manufacturer's protocols (ABI PRISM 7500 Detection System, Applied Biosystems). RPLP0 was used as endogenous control for normalization [37] . qRT-PCR was performed using the TaqMan gene expression assays (Applied Biosystems) (Table S2) as described in Italiano et al. [6] . The primers used for SYBRGreen experiments are described in Supplementary Table S3 . The comparative threshold cycle method was used to achieve relative quantification of gene expression [6] .
Results
Conventional and spectral karyotype: hypertriploid genome containing giant marker chromosomes
Cytogenetic analysis of the primary culture of the 95T1000 WDLPS showed a near-diploid karyotype. The number of chromosomes ranged from 45 to 49 after 10 days of culture. One or two giant marker chromosomes were observed in metaphase cells (Fig. 2a) . Several structural abnormalities that were not identifiable by conventional banding techniques were also observed. At P80, the karyotype was hypertriploid; the number of chromosomes ranged from 62 to 89, with a modal number of 79. We observed one or two giant marker chromosomes apparently similar to those observed in the primary culture. In addition, several structural and numerical abnormalities were observed (Fig. 2b) . These anomalies were too complex to be correctly interpreted by means of conventional cytogenetics and were characterized by SKY analysis that showed a variety of clonal and nonclonal aberrations (Fig. 2c) . Both intra-and interchromosomal anomalies were observed. The extremities of the giant markers had variable origins: they were most frequently composed of sequences from chromosome 14 and intermittently from chromosomes 1, 5, 6, and 11 ( Fig. 2d and Table S4 ). The SKY method was not appropriate to identify the central region of the giant markers because the dyes were too closely intermixed for providing an interpretable pattern. The co-amplification of sequences from chromosomes 10 and 12 that constitutes the core of these giant markers was eventually identified by aCGH and complementary FISH analyses (see below).
Among abnormally sized chromosomes apparently composed of unique chromosome material, aberrant chromosomes 1, 2, 3, 4, 7, 10, 11, 12, 13, 16, 18, 20, 21, and 22 were frequently observed. In addition to the marker chromosomes with 10p-12q amplification mentioned above, 15 recurrent derivative chromosomes showing interchromosomal rearrangements were identified (Table 2 and Fig. S1 ). The derivative chromosomes A, F, H, J, and O were sometimes duplicated. Most derivative chromosomes were made up of two to three different chromosomes while the derivative B and C resulted from more complex rearrangements. Evidence for chromosomal instability was suggested by the heterogeneous presence of various derivative chromosomes within the different metaphase cells analyzed (Table 2) , as well as variation in the number of giant markers (Table S4) . 
The detailed aCGH profile of losses, gains, and amplifications was identified across the genome (Fig. 3a and Supplementary Table S1 ). The most significant imbalances were represented by high-level amplification of chromosomes 10 and 12 (ECN higher than 10) . (Fig. 3b) . A total of 45 segments showing various levels of gain and amplification (from 6 to 55 ECN) and sizes (from 30 kb to 0.7 Mb; average, 0.5 Mb) were identified (Table 3) . Overall, these segments included 62 amplified genes.
The amplified regions from the long arm of chromosome 12 spanned 82 Mb from 12q12 to 12q24.21 ( Fig. 3c) and consisted of 67 independent amplified segments; the size of which ranged from 70 kb to 2.4 Mb (average, 0.4 Mb; total size, 27.8 Mb). The ECN ranged from 3 to 57 (average, 18) (Table 3) . Overall, these segments contained 370 amplified genes including CDK4, TSPAN31 (12q14.1), GNS, WIF1, HMGA2 (12q14.3), MDM2, CPM YEATS4, and FRS2 (12q15). In contrast, GLI1 and DDIT3 (12q13.3) were not amplified (Fig. 3c) .
No losses were observed except for a 1.3-Mb segment at 20p13 and a 3.4-Mb segment at 20q13.32-q13. 33 . On the proximal side of the 20q13-deleted segment, a moderate gain (4 ECN) of 16 Mb was observed. Chromosomes 4, 13, and 17 showed similar profiles characterized by moderate gain of long segments (from 3 to 7 ECN) across the full chromosome length (Table 3, S1 ).
Comprehensive structural analysis of amplified 10p and 12q segments within the giant marker chromosomes
The 10p-and 12q-amplified sequences were colocated and intermixed in the central region of the giant marker chromosome as well as in a few other marker chromosomes (B, C, G, J, and O) as shown by FISH analysis with WCP 10 and 12 probes as well as several locusspecific probes, such as RP11-150J3 (FRMD4A; 10p13), RP11-177H22 (MLLT10; 10p12.31), RP11-269B1 (NEBL; 10p12.31), and MDM2 (12q15) (Fig. 4) . Discontinuities in the 10p-and 12q-amplified regions were detected by shifts of amplification levels nearby or within several genes: for instance, BAC clone RP11-34I5 (10p12.31) that contained the 3′ region of NEBL did not show an amplified signal in contrast to the high amplification detected for clone RP11-269B1 that contained most part of the NEBL gene. A structural rearrangement was also detected in the vicinity of HMGA2: while probes containing exons 1 to 5 (RP11-299L9, RP11-23C9, and CTC-782I9) and the telomeric side of the 3′ extremity of HMGA2 (RP11-118B13) showed highly amplified signals, only a few gained copies were observed with RP11-30I11 probe, located on the centromeric side of the 5′ extremity of HMGA2 (Fig. 4f) . In addition, it is noteworthy that the giant marker did not contain any alpha-satellite sequences, suggesting the presence of an analphoid neocentromere (not shown).
Secondary chromosomal anomalies: complementary FISH analyses
The centromeric probes for chromosomes 3, 7, 9, and 17 showed a signal pattern consistent with the hypertriploid karyotype ( Table 1) . Four copies of each were identified on normal and abnormal chromosomes, respectively. The probes for chromosome 9 showed not only a pattern consistent with hypertriploidy, but also the presence of structural rearrangements. The CDKN2A locus (9p21) was disomic, indicating a relative loss of the 9p21 region since four chromosome 9 centromeres were observed. This loss was not detected by aCGH analysis, presumably because of a low statistical significance value related with the polyploidy of the specimen (Table S1 ). MAP3K5 (ASK1) (6q23.3) and JUN (1p32.1) loci showed no imbalance, in concordance with the aCGH results ( Table 1, S1 ). The CCND1 gene was duplicated on abnormal derivative chromosomes 11. The interstitial gains of chromosome 13 long arm detected by aCGH were confirmed by FISH analysis, which showed two to six signals per cell for the CTD-2328A22 probe (13q34), while more than ten signals were observed with the RP11-313L9 probe (13q33.3-13q34) (not shown).
qRT-PCR
We have detected strong overexpression of the following genes: MDM2, CDK4, YEATS4, HMGA2, TSPAN31, and WIF1 and no overexpression of GLI1 and DDIT3 (Table 4) . Among the overexpressed genes from 12q region, WIF1 showed the highest fold change (1,733, in comparison to normal adipose tissue). All the five exons of HMGA2 showed overexpression (fold change values, 317 for exons 1 and 2 and 65 for exons 3 to 5, respectively). Genes of the RB1 pathway, such as CCND1, CDK4, CDKN2A (p14ARF and p16INK4a), were overexpressed, whereas RB1 was not.
Discussion
We describe a novel WDLPS cell line designated 95T1000. This cell line was established spontaneously from primary cultures of a recurring sclerosing WDLPS and contained high-level amplification of the 12q14-15 region located on supernumerary giant marker chromosomes. The patient had received adjuvant radiotherapy following the excision of the primary liposarcoma and also a preoperative dose of 45 Gy prior to the excision of the first recurrent tumor that was used for establishing the cell line. This first recurrence did not present the features of a radiation-induced liposarcoma, since it was histologically similar to the primary tumor and with a near diploid karyotype, including the characteristic [5, 9, 10, 13-16, 21, 22, 26, 29, 30, 38-41] . Consequently, detection of 12q amplified genes is widely used for distinguishing WDLPS/DDLPS from other tumors. This detection can be done by FISH [15] , Q-PCR [42] , or aCGH [4] and indirectly by immunohistochemistry [43, 44] . MDM2 has early been identified as the main driver gene of the WDLPS/DDLPS amplicon since it is consistently amplified in all cases of WDLPS and DDLPS [10, 43, 45, 46] . The overexpression of MDM2 protein generated by the genomic amplification inactivates TP53. Indeed, MDM2 targets TP53 degradation toward the proteasome and inhibits P53-mediated transactivation [47] . Pharmaceutical compounds, such as nutlin, are currently being tested for the purpose of blocking the P53 inactivation mediated by MDM2 [48] .
Despite its obvious major contribution, the amplification of MDM2 does not seem to be sufficient by itself to account for the pathogenesis of WDLPS/DDLPS. Other genes from the 12q14-15 region are co-amplified and co-expressed with MDM2 [7, 10, [49] [50] [51] . Similarly, a number of previously described WDLPS/DDLPS cases have identified giant marker chromosomes of comparable size to that in the 95T1000 cell line that also contained amplification of CDK4 and HMGA2. CDK4 is not consistently amplified in WDLPS/DDLPS. It is amplified only in approximately 85 % of cases [1, 6, 7, 10, 30] . The absence of CDK4 amplification in WDLPS has been correlated to low-grade lipoma-like tumors of peripheral location and a better outcome [7] . In the present case, although the primary tumor was located peripherally, it had a high potential of recurrence that might be related to CDK4 amplification and overexpression.
We observed amplification of the 5 exons as well as the 3′ region of HMGA2 and this amplification resulted in the overexpression of the whole gene. It is noteworthy that the region immediately proximal to the 5′ part of HMGA2 was not amplified (Fig. 4f) . Structural rearrangements of HMGA2 have initially been described in lipomas where they often consist in breakage within the third intron followed by fusion with various partner genes [52] [53] [54] . It was later shown that anomalies of HMGA2 were not confined to benign adipose tumors since HMGA2 was recurrently amplified, rearranged, and overexpressed in WDLPS/DDLPS [6, [55] [56] [57] [58] [59] . Although various ectopic sequences can be fused to HMGA2 in WDLPS [56] , it does not appear that bona fide fusion genes are present in WDLPS as they often are in lipomas. However, it has been shown that in lipomas as well as in other tumors, overexpression of HMGA2 is not always generated by fusion genes [60] [61] [62] [63] . The overexpression of HMGA2 is a feature shared by both lipomas and WDLPS, though resulting from distinct events. The exact underlying mechanisms of dysregulation that makes HMGA2 a central gene in differentiated adipose tumors still remain to be elucidated.
Overall, the size of the 95T1000 12q amplicon was large, comprising 370 genes. This is more than twice the number of amplified 12q genes found in the WDLPS cell line described by Persson et al. [30] , but similar to the number observed in 93T449 and 94T778 WDLPS cell lines [23; D.M. Thomas, personal communication]. Among these amplified genes, we have found amplification of TSPAN31, GNS, WIF1, CPM, YEATS4, and FRS2 as recurrently described in WDLPS/DDLPS [6, 7, 10, 30] .
In addition to the amplification of 12q genes, we have found a high-level amplification of the 10p chromosomal region. The finding of co-amplification of at least one chromosomal region other than 12q14-15 [5, 6, 8, 9, [12] [13] [14] [16] [17] [18] [19] [20] [21] [22] is a recurrent feature of WDLPS/ DDLPS. These "extra-12q14-15" co-amplified regions are variable among patients. The most frequent and most studied are 6q23, 1p32, and 1q23-24. While the amplification of MAP3K5 at 6q23 and JUN at 1p32 has been correlated to the presence of a poorly differentiated component [17, 22, 29, 40, 41] , the significance and role of other genomic regions that are co-amplified with 12q14-15 are not elucidated. We have emitted the hypothesis these co-amplified regions might provide neocentromeric sequences to the giant markers that lack alpha-satellite sequences [15, 23] . The 1q23-24 amplicon [30, 56] has been recently suggested to be associated more frequently with WDLPS/DDLPS lacking CDK4 amplification [7, 64] . The 10p11-14 region is rarely co-amplified with 12q in WDLPS/DDLPS, only a handful of cases have been described [22, 65] . In the 95T1000 cells, the 10p amplicon contained 62 genes. It was smaller than the 12q amplicon (27 Mb) but reached similar ECN. It also displayed a discontinuous pattern. Among the amplified genes, several of them are of interest because of their oncogenic functions. In particular, we found amplification of the oncogene MLLT10. This gene, previously called AF10 encodes a transcription factor and is a fusion partner of MLL in acute leukemias with t(10;11)(p12;q23) [66, 67] . It has also been described to fuse with PICALM (11q14.2) in various hematologic malignancies, including acute lymphoblastic and myeloblastic leukemias and diffuse histiocytic lymphomas. In addition, MLLT10 is a susceptibility locus for meningioma [68] . The NEBL gene that codes for nebulette protein highly expressed in cardiac muscle [69] is also amplified in 95T1000 cells. This gene is located closely nearby MLLT10 and has also been described to be a fusion partner of MLL in a case of infant leukemia [70] . Another interesting oncogene contained in the 10p amplicon was BMI1. It encodes a polycomb-group protein involved in a multiprotein complex that represses the transcription of developmental genes, such as Hox genes. BMI1 is required for proliferation of both normal and leukemic stem cells [71] . It is expressed in a variety of malignancies such as lymphoma, leukemia, carcinoma, medulloblastoma, as well as glioblastoma and has been shown to be moderately amplified in some cases of mantle cell lymphoma and gained in gliomas [72] .
In conclusion, we describe here the genetic features of a novel WDLPS cell line characterized by typical 12q amplification. We provide a comprehensive description of the chromosomal anomalies present in these cells by using a panel of molecular cytogenetics methods. Notably, this cell line harbors an original amplification of the 10p11-14 region. Future studies on genes contained within this region will hopefully shed light on the pathogenesis of WDLPS.
